Literature DB >> 8618685

Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease.

Y Nagai1, S Ueno, Y Saeki, F Soga, M Hirano, T Yanagihara.   

Abstract

We investigated the dopamine receptor (DAR) mRNA expression in peripheral blood lymphocytes from 45 patients with Parkinson's disease (PD) and 21 age-matched controls using the quantitative reverse transcription and polymerase chain reaction method. Beta-actin mRNA was used as an internal control to evaluate the relative expression level of the DAR mRNA. There was a statistically significant decrease of the D3 dopamine receptor (D3R) mRNA expression in PD patients compared with that in controls. There was no change in expression of the D5 dopamine reception mRNA in PD patients. A further binding study showed reduction of the D3R binding sites in PD lymphocytes. The decrease of the D3R mRNA expression correlated with the degree of clinical severity in PD patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8618685     DOI: 10.1212/wnl.46.3.791

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  44 in total

1.  Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray.

Authors:  Silvia Mandel; Edna Grünblatt; Gila Maor; Moussa B H Youdim
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

Review 2.  Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.

Authors:  Carmen Noelker; Harald Hampel; Richard Dodel
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

3.  mRNA expression of dopamine receptors in peripheral blood lymphocytes of computer game addicts.

Authors:  Nasim Vousooghi; Seyed Zeinolabedin Zarei; Mitra-Sadat Sadat-Shirazi; Fatemeh Eghbali; Mohammad Reza Zarrindast
Journal:  J Neural Transm (Vienna)       Date:  2015-05-14       Impact factor: 3.575

Review 4.  Where Is Dopamine and how do Immune Cells See it?: Dopamine-Mediated Immune Cell Function in Health and Disease.

Authors:  S M Matt; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2019-05-11       Impact factor: 4.147

5.  D1 and D2 dopamine receptor-mediated inhibition of activated normal T cell proliferation is lost in jurkat T leukemic cells.

Authors:  Biswarup Basu; Chandrani Sarkar; Debanjan Chakroborty; Subhalakshmi Ganguly; Saurav Shome; Partha Sarathi Dasgupta; Sujit Basu
Journal:  J Biol Chem       Date:  2010-06-30       Impact factor: 5.157

Review 6.  Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?

Authors:  Marina Romero-Ramos; Marianne von Euler Chelpin; Vanesa Sanchez-Guajardo
Journal:  Hum Vaccin Immunother       Date:  2014-03-26       Impact factor: 3.452

7.  Molecular markers of early Parkinson's disease based on gene expression in blood.

Authors:  Clemens R Scherzer; Aron C Eklund; Lee J Morse; Zhixiang Liao; Joseph J Locascio; Daniel Fefer; Michael A Schwarzschild; Michael G Schlossmacher; Michael A Hauser; Jeffery M Vance; Lewis R Sudarsky; David G Standaert; John H Growdon; Roderick V Jensen; Steven R Gullans
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-10       Impact factor: 11.205

8.  Transcriptome Profile Changes in Mice with MPTP-Induced Early Stages of Parkinson's Disease.

Authors:  Anelya Kh Alieva; Elena V Filatova; Anna A Kolacheva; Margarita M Rudenok; Petr A Slominsky; Mikhail V Ugrumov; Maria I Shadrina
Journal:  Mol Neurobiol       Date:  2016-10-18       Impact factor: 5.590

Review 9.  Chipping away at diagnostics for neurodegenerative diseases.

Authors:  Clemens R Scherzer
Journal:  Neurobiol Dis       Date:  2009-03-10       Impact factor: 5.996

10.  Prodromal non-motor symptoms of Parkinson's disease.

Authors:  Clelia Pellicano; Dario Benincasa; Vincenzo Pisani; Francesca R Buttarelli; Morena Giovannelli; Francesco E Pontieri
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.